Summary

The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.
“Drug Discovery held the largest market share in the biosimulation market in 2023, by application.”
The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.
“By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period.”
By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.
“Asia Pacific is estimated to register the highest CAGR over the forecast period.”
The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.
Breakdown of supply-side primary interviews by company type, designation, and region:
• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: Managers (40%), Directors (35%), and Others (25%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)
List of Companies Profiled in the Report:
o Certara USA. (US)
o Simulations Plus. (US)
o Dassault Systèmes (France)
o Schrödinger, Inc. (US)
o Advanced Chemistry Development, Inc. (Canada)
o Chemical Computing Group ULC. (Canada)
o Rosa & Co. LLC. (US)
o Genedata AG (US)
o Physiomics Plc (United Kingdom)
o In Silico Biosciences. (US)
o Allucent. (US)
o OpenEye, Cadence Molecular Sciences. (US)
o Cellworks Group, Inc. (US)
o VeriSIM Life. (US)
o Netabolics SRL (Italy)
o Charnwood Discovery (United Kingdom)
o The MathWorks, Inc. (US)
o ANSYS, Inc (US)
o Instem Group of Companies (United Kingdom)
o Insilico Medicine (US)
o SCM – Software Chemistry & Materials (Netherlands)
o BioSymetrics, Inc. (Canada)
o Atomwise Inc. (US)
o insitro. US)
o Clinithink. (US)

Research Coverage:
This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the biosimulation market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 45
2.1.2.2 Insights from primary experts 46
2.2 MARKET SIZE ESTIMATION 47
2.3 DATA TRIANGULATION 51
2.4 MARKET SHARE ESTIMATION 52
2.5 RESEARCH ASSUMPTIONS 52
2.6 LIMITATIONS 52
2.6.1 METHODOLOGY-RELATED LIMITATIONS 52
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 60
4.1 BIOSIMULATION MARKET OVERVIEW 60
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023) 61
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024−2029) 62
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
 
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 65
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies 65
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP) 65
5.2.1.4 Need to curtail drug discovery and development costs 66
5.2.1.5 Growth in biologics and biosimilars markets 66
5.2.2 RESTRAINTS 67
5.2.2.1 Lack of standardization 67
5.2.2.2 Data availability and quality 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Emerging applications 67
5.2.3.2 Use of biosimulation solutions for pediatric drug development 68
5.2.4 CHALLENGES 68
5.2.4.1 Difficulties in matching complexity of biological systems and processes 68
5.2.4.2 Shortage of biosimulation and modeling experts 69
5.3 ECOSYSTEM ANALYSIS 69
5.3.1 SOFTWARE PROVIDERS 69
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES 69
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 69
5.3.4 REGULATORY BODIES 69
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS 69
5.4 CASE STUDY ANALYSIS 71
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING 71
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER 71
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE 72
5.5 VALUE CHAIN ANALYSIS 72
5.6 PORTER'S FIVE FORCES ANALYSIS 74
5.6.1 BARGAINING POWER OF SUPPLIERS 75
5.6.2 BARGAINING POWER OF BUYERS 75
5.6.3 THREAT OF SUBSTITUTES 75
5.6.4 THREAT OF NEW ENTRANTS 75
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 75
 
5.7 REGULATORY ANALYSIS 76
5.7.1 REGULATORY LANDSCAPE 76
5.7.1.1 North America 76
5.7.1.2 Europe 77
5.7.1.3 Asia Pacific 77
5.7.1.4 Latin America 78
5.7.1.5 Middle East & Africa 78
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.8 PATENT ANALYSIS 81
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION 81
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 81
5.9 TECHNOLOGY ANALYSIS 82
5.9.1 KEY TECHNOLOGIES 82
5.9.1.1 Mathematical modeling 82
5.9.1.2 Software platforms 83
5.9.1.3 Quantitative systems pharmacology (QSP) 83
5.9.2 COMPLEMENTARY TECHNOLOGIES 83
5.9.2.1 Data analytics 83
5.9.2.2 Machine learning and AI 83
5.9.3 ADJACENT TECHNOLOGIES 83
5.9.3.1 In silico trials 83
5.10 INDUSTRY TRENDS 84
5.10.1 DISCOVERY OF BIOMARKERS 84
5.10.2 ADOPTION IN PERSONALIZED MEDICINE 84
5.11 PRICING ANALYSIS 84
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023 85
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE) 85
5.12 KEY CONFERENCES & EVENTS, 2024–2025 86
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.13.1 BUYING CRITERIA 87
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
5.15 END-USER ANALYSIS 88
5.15.1 UNMET NEEDS 88
5.15.2 END-USER EXPECTATIONS 89
5.16 INVESTMENT & FUNDING SCENARIO 90
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 90
5.17.1 KEY USE CASES 91
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92
5.17.2.1 Case study 92
5.17.2.2 Bioinformatics market 93
5.17.2.3 Drug discovery services market 93
5.17.2.4 Drug discovery informatics market 93
5.17.3 USER READINESS & IMPACT ASSESSMENT 93
5.17.3.1 User readiness 93
5.17.3.1.1 Pharmaceutical & biotechnology companies 93
5.17.3.1.2 Contract research organizations 94
5.17.3.2 Impact assessment 94
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies 94
5.17.3.2.1.1 Implementation 94
5.17.3.2.1.2 Impact 94
5.17.3.2.2 User B: Academic & research institutes 95
5.17.3.2.2.1 Implementation 95
5.17.3.2.2.2 Impact 95
6 BIOSIMULATION MARKET, BY OFFERING 96
6.1 INTRODUCTION 97
6.2 SOFTWARE 97
6.2.1 STANDALONE MODULES 98
6.2.1.1 Molecular modeling & simulation software 100
6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth 100
6.2.1.2 PK/PD modeling & simulation software 101
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth 101
6.2.1.3 PBPK modeling & simulation software 102
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market 102
6.2.1.4 Toxicity prediction software 103
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market 103
6.2.1.5 Clinical trial simulation software 104
6.2.1.5.1 High failure rate of clinical trials to accelerate growth 104
6.2.1.6 Other biosimulation software 105
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS 106
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms 106
6.3 SERVICES 107
6.3.1 CONSULTING & ADVISORY 109
6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services 109
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 110
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth 110
 
6.3.3 DATA ANALYSIS & INTERPRETATION 111
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services 111
7 BIOSIMULATION MARKET, BY APPLICATION 112
7.1 INTRODUCTION 113
7.2 DRUG DISCOVERY 113
7.2.1 TARGET IDENTIFICATION & VALIDATION 115
7.2.1.1 Need for identification of optimal targets in drug discovery to drive market 115
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION 116
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth 116
7.3 DRUG DEVELOPMENT 117
7.3.1 PRECLINICAL TESTING 118
7.3.1.1 PK/PD 120
7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market 120
7.3.1.2 ADME/Toxicology 121
7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth 121
7.3.2 CLINICAL TRIALS 122
7.3.2.1 Phase I 123
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth 123
7.3.2.2 Phase II 124
7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth 124
7.3.2.3 Phase III 125
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand 125
7.3.2.4 Phase IV/Post-marketing surveillance 126
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption 126
7.4 DISEASE MODELING 127
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH 127
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT 128
7.5.1 PRODUCTION PLANNING & OPTIMIZATION 130
7.5.1.1 Need for proper production planning and execution to drive market growth 130
7.5.2 QUALITY CONTROL & PROCESS MONITORING 131
7.5.2.1 Adherence to maintaining product quality to fuel market growth 131
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT 131
7.5.3.1 Need to forecast demand effectively to drive market growth 131
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING 132
7.5.4.1 Need to maintain operational continuity to support market growth 132
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS 133
7.6 OTHER APPLICATIONS 134
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 136
8.1 INTRODUCTION 137
8.2 ONCOLOGY 137
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH 137
8.3 CARDIOVASCULAR DISEASES 138
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET 138
8.4 NEUROLOGICAL DISORDERS 139
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 139
8.5 INFECTIOUS DISEASES 140
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 140
8.6 OTHER THERAPEUTIC AREAS 141
9 BIOSIMULATION MARKET, BY REVENUE MODEL 143
9.1 INTRODUCTION 144
9.2 LICENSE-BASED MODELS 144
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET 144
9.3 SUBSCRIPTION-BASED MODELS 145
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 145
9.4 SERVICE-BASED MODELS 146
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION 146
9.5 PAY-PER-USE MODELS 147
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH 147
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 149
10.1 INTRODUCTION 150
10.2 ON-PREMISE MODELS 150
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 150
10.3 CLOUD-BASED MODELS 151
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD 151
10.4 HYBRID MODELS 152
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION 152
11 BIOSIMULATION MARKET, BY END USER 154
11.1 INTRODUCTION 155
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 155
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 155
11.3 CONTRACT RESEARCH ORGANIZATIONS 156
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 156
11.4 ACADEMIC & RESEARCH INSTITUTES 157
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH 157
11.5 REGULATORY BODIES 158
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH 158
11.6 OTHER END USERS 159
12 BIOSIMULATION MARKET, BY REGION 161
12.1 INTRODUCTION 162
12.2 NORTH AMERICA 162
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 169
12.2.2 US 169
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 169
12.2.3 CANADA 175
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market 175
12.3 EUROPE 181
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 187
12.3.2 GERMANY 187
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation 187
12.3.3 UK 193
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 193
12.3.4 FRANCE 198
12.3.4.1 Growing R&D pipeline for clinical trials to drive market 198
12.3.5 ITALY 204
12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake 204
12.3.6 SPAIN 209
12.3.6.1 Established network of research centers to propel market 209
12.3.7 REST OF EUROPE 215
 
12.4 ASIA PACIFIC 220
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 227
12.4.2 CHINA 227
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market 227
12.4.3 INDIA 233
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation 233
12.4.4 JAPAN 239
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth 239
12.4.5 REST OF ASIA PACIFIC 244
12.5 LATIN AMERICA 249
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 255
12.5.2 BRAZIL 255
12.5.2.1 Advancing biosimulation in region to support market growth 255
12.5.3 MEXICO 260
12.5.3.1 Government initiatives to enhance digital health to propel market growth 260
12.5.4 REST OF LATIN AMERICA 265
12.6 MIDDLE EAST & AFRICA 270
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 276
12.6.2 GCC COUNTRIES 276
12.6.2.1 Increase in healthcare investments to support market growth 276
12.6.3 REST OF MIDDLE EAST & AFRICA 282
13 COMPETITIVE LANDSCAPE 289
13.1 INTRODUCTION 289
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 289
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET 290
13.3 REVENUE ANALYSIS, 2019–2023 291
13.4 MARKET SHARE ANALYSIS, 2023 291
13.4.1 CERTARA, USA (US) 293
13.4.2 DASSAULT SYSTÈMES (FRANCE) 293
13.4.3 SCHRÖDINGER, INC. (US) 293
13.4.4 SIMULATIONS PLUS (US) 293
13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA) 294
13.5 RANKING OF KEY MARKET PLAYERS 294
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 294
13.6.1 STARS 295
13.6.2 EMERGING LEADERS 295
13.6.3 PERVASIVE PLAYERS 295
13.6.4 PARTICIPANTS 295
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 297
13.6.5.1 Company footprint 297
13.6.5.2 Offering footprint 298
13.6.5.3 Application footprint 299
13.6.5.4 End-user footprint 300
13.6.5.5 Region footprint 301
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023 302
13.7.1 PROGRESSIVE COMPANIES 302
13.7.2 RESPONSIVE COMPANIES 302
13.7.3 DYNAMIC COMPANIES 302
13.7.4 STARTING BLOCKS 302
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 304
13.8 COMPANY EVALUATION & FINANCIAL METRICS 306
13.9 BRAND/PRODUCT COMPARISON 307
13.10 COMPETITIVE SCENARIO 308
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 308
13.10.2 DEALS 309
13.10.3 EXPANSIONS 310
13.10.4 OTHER DEVELOPMENTS 310
14 COMPANY PROFILES 311
14.1 KEY PLAYERS 311
14.1.1 CERTARA, USA 311
14.1.1.1 Business overview 311
14.1.1.2 Products & services offered 312
14.1.1.3 Recent developments 314
14.1.1.3.1 Product launches & enhancements 314
14.1.1.3.2 Deals 315
14.1.1.4 MnM view 316
14.1.1.4.1 Right to win 316
14.1.1.4.2 Strategic choices 316
14.1.1.4.3 Weaknesses & competitive threats 316
14.1.2 DASSAULT SYSTÈMES 317
14.1.2.1 Business overview 317
14.1.2.2 Products & services offered 318
14.1.2.3 Recent developments 319
14.1.2.3.1 Deals 319
14.1.2.4 MnM view 320
14.1.2.4.1 Right to win 320
14.1.2.4.2 Strategic choices 320
14.1.2.4.3 Weaknesses & competitive threats 320
 
14.1.3 SCHRÖDINGER, INC. 321
14.1.3.1 Business overview 321
14.1.3.2 Products & services offered 322
14.1.3.3 Recent developments 324
14.1.3.3.1 Deals 324
14.1.3.4 MnM view 325
14.1.3.4.1 Right to win 325
14.1.3.4.2 Strategic choices 325
14.1.3.4.3 Weaknesses & competitive threats 325
14.1.4 SIMULATIONS PLUS 326
14.1.4.1 Business overview 326
14.1.4.2 Products & services offered 327
14.1.4.3 Recent developments 331
14.1.4.3.1 Product launches & enhancements 331
14.1.4.3.2 Deals 332
14.1.4.3.3 Other developments 333
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. 334
14.1.5.1 Business overview 334
14.1.5.2 Products & services offered 334
14.1.5.3 Recent developments 335
14.1.5.3.1 Product launches & enhancements 335
14.1.5.3.2 Deals 335
14.1.6 CHEMICAL COMPUTING GROUP ULC 336
14.1.6.1 Business overview 336
14.1.6.2 Products & services offered 336
14.1.6.3 Recent developments 337
14.1.6.3.1 Deals 337
14.1.7 ROSA & CO. LLC 338
14.1.7.1 Business overview 338
14.1.7.2 Products & services offered 338
14.1.8 GENEDATA AG (A DANAHER COMPANY) 339
14.1.8.1 Business overview 339
14.1.8.2 Products & services offered 340
14.1.8.3 Recent developments 341
14.1.8.3.1 Product launches & enhancements 341
14.1.8.3.2 Deals 341
14.1.9 PHYSIOMICS PLC 342
14.1.9.1 Business overview 342
14.1.9.2 Products & services offered 343
14.1.9.3 Recent developments 344
14.1.9.3.1 Deals 344
 
14.1.10 IN SILICO BIOSCIENCES 345
14.1.10.1 Business overview 345
14.1.10.2 Products & services offered 345
14.1.11 ALLUCENT 346
14.1.11.1 Business overview 346
14.1.11.2 Products & services offered 346
14.1.11.3 Recent developments 347
14.1.11.3.1 Deals 347
14.1.11.3.2 Expansions 347
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES 348
14.1.12.1 Business overview 348
14.1.12.2 Products & services offered 349
14.1.12.3 Recent developments 350
14.1.12.3.1 Product enhancements 350
14.1.12.3.2 Deals 350
14.1.12.3.3 Expansions 351
14.1.13 CELLWORKS GROUP, INC. 352
14.1.13.1 Business overview 352
14.1.13.2 Products & services offered 352
14.1.13.3 Recent developments 353
14.1.13.3.1 Expansions 353
14.1.14 VERISIM LIFE 354
14.1.14.1 Business overview 354
14.1.14.2 Products & services offered 354
14.1.14.3 Recent developments 355
14.1.14.3.1 Deals 355
14.1.14.3.2 Other developments 355
14.1.15 NETABOLICS 356
14.1.15.1 Business overview 356
14.1.15.2 Products & services offered 356
14.1.16 CHARNWOOD DISCOVERY 357
14.1.16.1 Business overview 357
14.1.16.2 Products & services offered 357
14.1.16.3 Recent developments 358
14.1.16.3.1 Deals 358
14.1.17 THE MATHWORKS, INC. 359
14.1.17.1 Business overview 359
14.1.17.2 Products & services offered 359
14.1.17.3 Recent developments 360
14.1.17.3.1 Product enhancements 360
 
14.1.18 ANSYS, INC. 361
14.1.18.1 Business overview 361
14.1.18.2 Products & services offered 362
14.2 START-UP/SME PLAYERS 363
14.2.1 INSTEM GROUP OF COMPANIES 363
14.2.2 INSILICO MEDICINE 364
14.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS 365
14.2.4 BIOSYMETRICS, INC. 365
14.2.5 ATOMWISE INC. 366
14.2.6 INSITRO 366
14.2.7 CLINITHINK 367
15 APPENDIX 368
15.1 DISCUSSION GUIDE 368
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 374
15.3 CUSTOMIZATION OPTIONS 376
15.4 RELATED REPORTS 376
15.5 AUTHOR DETAILS 377